Want to see HK:1244 full AI Analyst Report?
3D Medicines, Inc. (1244) Stock Statistics & Valuation Metrics
Total Valuation
3D Medicines, Inc. has a market cap or net worth of HKD 673.84M. The enterprise value is HKD 471.71M.
- Market Cap
- HKD 673.84M
- Enterprise Value
- HKD 471.71M
Share Statistics
3D Medicines, Inc. has 258,177,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 258,177,000
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
3D Medicines, Inc.’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -16.14%.
- Return on Equity (ROE)
- -0.30
- Return on Assets (ROA)
- -0.19
- Return on Invested Capital (ROIC)
- -16.14%
- Return on Capital Employed (ROCE)
- -0.20
- Revenue Per Employee
- 2.20M
- Profits Per Employee
- -1.10M
- Employee Count
- 162
- Asset Turnover
- 0.38
- Inventory Turnover
- 16.28
Valuation Ratios
The current PE Ratio of 3D Medicines, Inc. is -3.11. 3D Medicines, Inc.’s PEG ratio is 0.68.
- PE Ratio
- -3.11
- PS Ratio
- 1.52
- PB Ratio
- 1.04
- Price to FCF
- -3.11
- Price to Operating Cash Flow
- -3.12
- PEG Ratio
- 0.68
Income Statement
In the last 12 months, 3D Medicines, Inc. had revenue of 356.09M and earned -177.53M in profits. Earnings per share was -0.72.
- Revenue
- 356.09M
- Gross Profit
- 298.97M
- Operating Income
- -112.65M
- Pretax Income
- -184.94M
- Net Income
- -177.53M
- EBITDA
- -191.18M
- Earnings Per Share (EPS)
- -0.72
Cash Flow
In the last 12 months, operating cash flow was -174.36M and capital expenditures -547,047, giving a free cash flow of -174.91M billion.
- Operating Cash Flow
- -174.36M
- Free Cash Flow
- -174.91M
- Free Cash Flow per Share
- -0.71
Dividends & Yields
3D Medicines, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -32.18%
- Earnings Yield
- -31.92%
Stock Price Statistics
- Beta
- 0.61
- 52-Week Price Change
- -58.96%
- 50-Day Moving Average
- 2.59
- 200-Day Moving Average
- 3.15
- Relative Strength Index (RSI)
- 51.19
- Average Volume (3m)
- 168.88K
Important Dates
3D Medicines, Inc. upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 31, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
3D Medicines, Inc. as a current ratio of 1.45, with Debt / Equity ratio of 25.60%
- Current Ratio
- 1.45
- Quick Ratio
- 1.44
- Debt to Market Cap
- 0.12
- Net Debt to EBITDA
- 0.09
- Interest Coverage Ratio
- -22.12
Taxes
In the past 12 months, 3D Medicines, Inc. has paid -53.58K in taxes.
- Income Tax
- -53.58K
- Effective Tax Rate
- 0.00
Enterprise Valuation
3D Medicines, Inc. EV to EBITDA ratio is -3.40, with an EV/FCF ratio of -3.23.
- EV to Sales
- 1.58
- EV to EBITDA
- -3.40
- EV to Free Cash Flow
- -3.23
- EV to Operating Cash Flow
- -3.24
Balance Sheet
3D Medicines, Inc. has HKD 394.59M in cash and marketable securities with HKD 171.36M in debt, giving a net cash position of HKD 223.23M billion.
- Cash & Marketable Securities
- HKD 394.59M
- Total Debt
- HKD 171.36M
- Net Cash
- HKD 223.23M
- Net Cash Per Share
- HKD 0.86
- Tangible Book Value Per Share
- HKD 1.91
Margins
Gross margin is 88.53%, with operating margin of -22.61%, and net profit margin of -48.51%.
- Gross Margin
- 88.53%
- Operating Margin
- -22.61%
- Pretax Margin
- -50.56%
- Net Profit Margin
- -48.51%
- EBITDA Margin
- -46.55%
- EBIT Margin
- -50.33%
Analyst Forecast
The average price target for 3D Medicines, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -17.22%
- EPS Growth Forecast
- -6.13%
Scores
- Smart Score
- 3
- AI Score
- 52